| Symbol | CMPX |
|---|---|
| Name | COMPASS THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 80 GUEST STREET,SUITE 601, BOSTON, Massachusetts, 02135, United States |
| Telephone | +1 617 500-8099 |
| Fax | — |
| — | |
| Website | https://www.compasstherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001738021 |
| Description | Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. The company has drugged over 40 immune targets and generated a diverse pipeline of monoclonal and multispecific therapeutic candidates with potential to transform care for patients with cancer or autoimmune diseases. Additional info from NASDAQ: |
2026-05-05 11:30
(30% Negative) COMPASS THERAPEUTICS, INC. (CMPX) Reports Q2 2026 Financial Results
Read more
2026-05-05 11:30
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
Read more
2026-04-30 17:01
New Form 4/A - Compass Therapeutics, Inc. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001171843-26-002894 <b>Size:</b> 5 KB
Read more
2026-04-29 21:11
Anderman Jonathan 🟢 acquired 25.0K shares of Compass Therapeutics, Inc. (CMPX) at $1.89 Transaction Date: Apr 29, 2026 | Filing ID: 002840
Read more
2026-04-29 20:58
Lerner Neil 🟢 acquired 15.0K shares of Compass Therapeutics, Inc. (CMPX) at $1.89 Transaction Date: Apr 29, 2026 | Filing ID: 002834
Read more
2026-04-29 09:15
New Form ARS - Compass Therapeutics, Inc. <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0001140361-26-017651 <b>Size:</b> 4 MB
Read more
2026-04-29 09:09
New Form DEFA14A - Compass Therapeutics, Inc. <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0001140361-26-017650 <b>Size:</b> 985 KB
Read more
2026-04-29 09:09
New Form DEF 14A - Compass Therapeutics, Inc. <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0001140361-26-017649 <b>Size:</b> 5 MB
Read more
2026-04-27 11:30
(90% Positive) COMPASS THERAPEUTICS, INC. (CMPX) Announces Enrollment Update for reduction Due to Patient Enrollment Issues, Regulatory Process, Safety Review
Read more
2026-04-27 11:30
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07392957 | Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblasto… | Phase1 | Glioblastoma | Not_Yet_Recruiting | 2026-04-30 | 2031-04-30 | ClinicalTrials.gov |
| NCT07392957 | Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblasto… | Phase1 | Glioblastoma | Not_Yet_Recruiting | 2026-04-30 | 2031-04-30 | ClinicalTrials.gov |
| NCT07419841 | A Phase 1 Study of the Safety and Tolerability of CTX-10726 | Phase1 | Gastroesophageal Cancer (GC) | Recruiting | 2026-04-01 | 2028-11-01 | ClinicalTrials.gov |
| NCT07419841 | A Phase 1 Study of the Safety and Tolerability of CTX-10726 | Phase1 | Gastroesophageal Cancer (GC) | Recruiting | 2026-04-01 | 2028-11-01 | ClinicalTrials.gov |
| NCT07213102 | Transform + Family Academy Randomized Controlled Trial in the Philippines | Na | Child Development | Not_Yet_Recruiting | 2025-11-01 | 2027-05-30 | ClinicalTrials.gov |
| NCT07213102 | Transform + Family Academy Randomized Controlled Trial in the Philippines | Na | Child Development | Not_Yet_Recruiting | 2025-11-01 | 2027-05-30 | ClinicalTrials.gov |
| NCT06689839 | Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR | Na | Aortic Stenosis Treated With TAVI | Recruiting | 2025-09-09 | 2027-01-01 | ClinicalTrials.gov |
| NCT06689839 | Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR | Na | Aortic Stenosis Treated With TAVI | Recruiting | 2025-09-09 | 2027-01-01 | ClinicalTrials.gov |
| NCT06548412 | CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Pa… | Phase1 | Metastatic Biliary Tract Cancer | Recruiting | 2025-01-22 | 2029-05-01 | ClinicalTrials.gov |
| NCT06548412 | CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Pa… | Phase1 | Metastatic Biliary Tract Cancer | Recruiting | 2025-01-22 | 2029-05-01 | ClinicalTrials.gov |
| NCT06247839 | The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major De… | Phase3 | Major Depressive Disorder | Recruiting | 2024-09-10 | 2026-06-30 | ClinicalTrials.gov |
| NCT06247839 | The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major De… | Phase3 | Major Depressive Disorder | Recruiting | 2024-09-10 | 2026-06-30 | ClinicalTrials.gov |
| NCT06069661 | U.S. Multicenter Feasibility Trial of the F2 Filter and Delivery System for Emb… | Na | Aortic Stenosis | Withdrawn | 2024-06-01 | 2025-01-01 | ClinicalTrials.gov |
| NCT06069661 | U.S. Multicenter Feasibility Trial of the F2 Filter and Delivery System for Emb… | Na | Aortic Stenosis | Withdrawn | 2024-06-01 | 2025-01-01 | ClinicalTrials.gov |
| NCT06150664 | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | Phase1 | Non Small Cell Lung Cancer | Recruiting | 2024-03-19 | 2027-05-01 | ClinicalTrials.gov |
| NCT06150664 | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | Phase1 | Non Small Cell Lung Cancer | Recruiting | 2024-03-19 | 2027-05-01 | ClinicalTrials.gov |
| NCT05893082 | Multicenter Feasibility Trial of the F2 Filter and Delivery System for Embolic … | Na | Aortic Stenosis | Completed | 2023-09-12 | 2024-10-31 | ClinicalTrials.gov |
| NCT05893082 | Multicenter Feasibility Trial of the F2 Filter and Delivery System for Embolic … | Na | Aortic Stenosis | Completed | 2023-09-12 | 2024-10-31 | ClinicalTrials.gov |
| NCT05866640 | Feasibility Trial of the F2 Filter and Delivery System for Embolic Protection D… | Early_Phase1 | Aortic Stenosis | Recruiting | 2023-04-29 | 2026-01-30 | ClinicalTrials.gov |
| NCT05866640 | Feasibility Trial of the F2 Filter and Delivery System for Embolic Protection D… | Early_Phase1 | Aortic Stenosis | Recruiting | 2023-04-29 | 2026-01-30 | ClinicalTrials.gov |
| NCT05711940 | Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Partici… | Phase3 | Treatment Resistant Depression | Active_Not_Recruiting | 2023-02-14 | 2026-12-01 | ClinicalTrials.gov |
| NCT05711940 | Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Partici… | Phase3 | Treatment Resistant Depression | Active_Not_Recruiting | 2023-02-14 | 2026-12-01 | ClinicalTrials.gov |
| NCT05733546 | A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investig… | Phase2 | Major Depressive Disorder | Active_Not_Recruiting | 2023-01-30 | 2025-09-01 | ClinicalTrials.gov |
| NCT05733546 | A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investig… | Phase2 | Major Depressive Disorder | Active_Not_Recruiting | 2023-01-30 | 2025-09-01 | ClinicalTrials.gov |
| NCT05624268 | Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD | Phase3 | Treatment Resistant Depression | Active_Not_Recruiting | 2023-01-19 | 2026-04-01 | ClinicalTrials.gov |
| NCT05624268 | Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD | Phase3 | Treatment Resistant Depression | Active_Not_Recruiting | 2023-01-19 | 2026-04-01 | ClinicalTrials.gov |
| NCT05506943 | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unrese… | Phase2 | Biliary Tract Cancer | Completed | 2023-01-09 | 2026-01-21 | ClinicalTrials.gov |
| NCT05506943 | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unrese… | Phase2 | Biliary Tract Cancer | Completed | 2023-01-09 | 2026-01-21 | ClinicalTrials.gov |
| NCT05513742 | A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer | Phase2 | Metastatic Colorectal Cancer | Completed | 2022-12-08 | 2025-05-15 | ClinicalTrials.gov |
| NCT05513742 | A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer | Phase2 | Metastatic Colorectal Cancer | Completed | 2022-12-08 | 2025-05-15 | ClinicalTrials.gov |
| NCT05481736 | Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-… | Phase2 | Anorexia Nervosa | Completed | 2022-10-12 | 2024-11-18 | ClinicalTrials.gov |
| NCT05481736 | Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-… | Phase2 | Anorexia Nervosa | Completed | 2022-10-12 | 2024-11-18 | ClinicalTrials.gov |
| NCT05381974 | The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatmen… | Phase2 | Treatment-Resistant Major Depressive Disorder | Withdrawn | 2022-09-15 | 2023-06-01 | ClinicalTrials.gov |
| NCT05381974 | The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatmen… | Phase2 | Treatment-Resistant Major Depressive Disorder | Withdrawn | 2022-09-15 | 2023-06-01 | ClinicalTrials.gov |
| NCT05312151 | The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stre… | Phase2 | Post Traumatic Stress Disorder | Completed | 2022-06-10 | 2024-02-12 | ClinicalTrials.gov |
| NCT05312151 | The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stre… | Phase2 | Post Traumatic Stress Disorder | Completed | 2022-06-10 | 2024-02-12 | ClinicalTrials.gov |
| NCT05220410 | The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depr… | Phase2 | Treatment Resistant Depression | Completed | 2022-03-28 | 2025-05-12 | ClinicalTrials.gov |
| NCT05220410 | The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depr… | Phase2 | Treatment Resistant Depression | Completed | 2022-03-28 | 2025-05-12 | ClinicalTrials.gov |
| NCT04825522 | The Effect of Intrawound Vancomycin Powder in Spine Surgery | Phase4 | Spine Disease | Recruiting | 2022-03-27 | 2028-12-01 | ClinicalTrials.gov |
| NCT04825522 | The Effect of Intrawound Vancomycin Powder in Spine Surgery | Phase4 | Spine Disease | Recruiting | 2022-03-27 | 2028-12-01 | ClinicalTrials.gov |
| NCT05070078 | The Single Assessment Numeric Evaluation (SANE) for Lumbar Discectomy | — | Lumbar Discectomy | Recruiting | 2021-11-10 | 2028-12-10 | ClinicalTrials.gov |
| NCT05070078 | The Single Assessment Numeric Evaluation (SANE) for Lumbar Discectomy | — | Lumbar Discectomy | Recruiting | 2021-11-10 | 2028-12-10 | ClinicalTrials.gov |
| NCT04661514 | Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy | Phase2 | Anorexia Nervosa | Completed | 2021-05-01 | 2022-06-10 | ClinicalTrials.gov |
| NCT04661514 | Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy | Phase2 | Anorexia Nervosa | Completed | 2021-05-01 | 2022-06-10 | ClinicalTrials.gov |
| NCT04433845 | The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disor… | Phase2 | Treatment Resistant Depression | Unknown | 2021-03-01 | 2023-04-15 | ClinicalTrials.gov |
| NCT04433845 | The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disor… | Phase2 | Treatment Resistant Depression | Unknown | 2021-03-01 | 2023-04-15 | ClinicalTrials.gov |
| NCT04433858 | An Open Label Study of the Safety and Efficacy of Psilocybin in Participants Wi… | Phase2 | Treatment Resistant Depression | Active_Not_Recruiting | 2021-03-01 | 2026-05-01 | ClinicalTrials.gov |
| NCT04433858 | An Open Label Study of the Safety and Efficacy of Psilocybin in Participants Wi… | Phase2 | Treatment Resistant Depression | Active_Not_Recruiting | 2021-03-01 | 2026-05-01 | ClinicalTrials.gov |
| NCT04656301 | Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder | Phase2 | Body Dysmorphic Disorders | Completed | 2021-02-26 | 2022-11-02 | ClinicalTrials.gov |
| NCT04656301 | Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder | Phase2 | Body Dysmorphic Disorders | Completed | 2021-02-26 | 2022-11-02 | ClinicalTrials.gov |
| NCT04203992 | Videogame for the Prevention of Doping and Supplement Abuse in Teenage Athletes | Na | Doping in Sport | Unknown | 2020-11-01 | 2022-06-01 | ClinicalTrials.gov |
| NCT04203992 | Videogame for the Prevention of Doping and Supplement Abuse in Teenage Athletes | Na | Doping in Sport | Unknown | 2020-11-01 | 2022-06-01 | ClinicalTrials.gov |
| NCT04739865 | The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants … | Phase2 | Treatment Resistant Depression | Completed | 2020-08-10 | 2021-10-14 | ClinicalTrials.gov |
| NCT04739865 | The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants … | Phase2 | Treatment Resistant Depression | Completed | 2020-08-10 | 2021-10-14 | ClinicalTrials.gov |
| NCT04519957 | Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU) | — | Treatment Resistant Depression | Completed | 2020-07-20 | 2022-08-11 | ClinicalTrials.gov |
| NCT04519957 | Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU) | — | Treatment Resistant Depression | Completed | 2020-07-20 | 2022-08-11 | ClinicalTrials.gov |
| NCT04492033 | A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Adv… | Phase1 | P1b: Advanced Solid Tumors | Terminated | 2020-06-22 | 2025-01-09 | ClinicalTrials.gov |
| NCT04492033 | A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Adv… | Phase1 | P1b: Advanced Solid Tumors | Terminated | 2020-06-22 | 2025-01-09 | ClinicalTrials.gov |
| NCT03881488 | Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patie… | Phase1 | Locally Advanced Solid Tumor | Completed | 2019-05-17 | 2025-05-21 | ClinicalTrials.gov |
| NCT03881488 | Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patie… | Phase1 | Locally Advanced Solid Tumor | Completed | 2019-05-17 | 2025-05-21 | ClinicalTrials.gov |
| NCT03775200 | The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant … | Phase2 | Treatment Resistant Depression | Completed | 2019-03-01 | 2021-09-27 | ClinicalTrials.gov |
| NCT03775200 | The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant … | Phase2 | Treatment Resistant Depression | Completed | 2019-03-01 | 2021-09-27 | ClinicalTrials.gov |
| NCT03634163 | Compassionate Communities Neighbourhood Program | Na | Chronic Disease | Unknown | 2018-09-01 | 2021-03-31 | ClinicalTrials.gov |
| NCT03634163 | Compassionate Communities Neighbourhood Program | Na | Chronic Disease | Unknown | 2018-09-01 | 2021-03-31 | ClinicalTrials.gov |
| NCT05107323 | Feasibility and Effectiveness Study of a Compassionate Mind Training Program fo… | Na | Teachers | Completed | 2018-04-01 | 2019-08-30 | ClinicalTrials.gov |
| NCT05107323 | Feasibility and Effectiveness Study of a Compassionate Mind Training Program fo… | Na | Teachers | Completed | 2018-04-01 | 2019-08-30 | ClinicalTrials.gov |
Total clinical trials: 66
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| F2 filter and delivery system | Other | Phase EARLY_PHASE1 | Aortic Stenosis | RECRUITING | NCT05866640 |
| F2 filter and delivery system | Other | Phase EARLY_PHASE1 | Aortic Stenosis | RECRUITING | NCT05866640 |
| Quality of Life Assessment | Other | Approved | Chronic Disease | UNKNOWN | NCT03634163 |
| Neighbourhood exchange | Other | Approved | Chronic Disease | UNKNOWN | NCT03634163 |
| Quality of Life Assessment | Other | Approved | Chronic Disease | UNKNOWN | NCT03634163 |
| Neighbourhood exchange | Other | Approved | Chronic Disease | UNKNOWN | NCT03634163 |
| Control | Other | Approved | Doping in Sport | UNKNOWN | NCT04203992 |
| Videogame | Other | Approved | Doping in Sport | UNKNOWN | NCT04203992 |
| Control | Other | Approved | Doping in Sport | UNKNOWN | NCT04203992 |
| Videogame | Other | Approved | Doping in Sport | UNKNOWN | NCT04203992 |
| Compassionate Mind Training for Teachers | Other | Approved | Teachers | COMPLETED | NCT05107323 |
| Compassionate Mind Training for Teachers | Other | Approved | Teachers | COMPLETED | NCT05107323 |
| Psilocybin | Other | Phase PHASE2 | Anorexia Nervosa | COMPLETED | NCT04661514 |
| Psilocybin | Other | Phase PHASE2 | Treatment Resistant Depression | UNKNOWN | NCT04433845 |
| Psilocybin | Other | Phase PHASE2 | Treatment Resistant Depression | UNKNOWN | NCT04433845 |
| Psilocybin | Other | Phase PHASE2 | Body Dysmorphic Disorders | COMPLETED | NCT04656301 |
| Psilocybin | Other | Phase PHASE2 | Body Dysmorphic Disorders | COMPLETED | NCT04656301 |
| Psilocybin | Other | Phase PHASE2 | Treatment Resistant Depression | COMPLETED | NCT03775200 |
| Psilocybin | Other | Phase PHASE2 | Treatment Resistant Depression | COMPLETED | NCT03775200 |
| Psilocybin | Other | Phase PHASE2 | Treatment Resistant Depression | COMPLETED | NCT03775200 |
| Psilocybin | Other | Phase PHASE2 | Treatment Resistant Depression | COMPLETED | NCT04739865 |
| Psilocybin | Other | Phase PHASE2 | Treatment Resistant Depression | COMPLETED | NCT04739865 |
| Psilocybin | Other | Phase PHASE2 | Treatment-Resistant Major Depressive Disorder | WITHDRAWN | NCT05381974 |
| Vancomycin | Other | Phase PHASE4 | Spine Disease | RECRUITING | NCT04825522 |
| Vancomycin | Other | Phase PHASE4 | Spine Disease | RECRUITING | NCT04825522 |
| Vancomycin | Other | Phase PHASE4 | Spine Disease | RECRUITING | NCT04825522 |
| Psilocybin | Other | Phase PHASE2 | Treatment Resistant Depression | ACTIVE_NOT_RECRUITING | NCT04433858 |
| Psilocybin | Other | Phase PHASE2 | Treatment Resistant Depression | ACTIVE_NOT_RECRUITING | NCT04433858 |
| Psilocybin | Other | Phase PHASE2 | Anorexia Nervosa | COMPLETED | NCT05481736 |
| Irinotecan | Other | Phase PHASE1 | P1b: Advanced Solid Tumors | TERMINATED | NCT04492033 |
| Paclitaxel | Other | Phase PHASE1 | P1b: Advanced Solid Tumors | TERMINATED | NCT04492033 |
| CTX-009 (ABL001) | Other | Phase PHASE1 | P1b: Advanced Solid Tumors | TERMINATED | NCT04492033 |
| F2 Filter and Delivery System | Other | Approved | Aortic Stenosis | COMPLETED | NCT05893082 |
| F2 Filter and Delivery System | Other | Approved | Aortic Stenosis | COMPLETED | NCT05893082 |
| Aortic Stenosis | Other | Approved | Aortic Stenosis | WITHDRAWN | NCT06069661 |
| Aortic Stenosis | Other | Approved | Aortic Stenosis | WITHDRAWN | NCT06069661 |
| Paclitaxel | Other | Phase PHASE2 | Biliary Tract Cancer | ACTIVE_NOT_RECRUITING | NCT05506943 |
| CTX-009 | Other | Phase PHASE2 | Biliary Tract Cancer | ACTIVE_NOT_RECRUITING | NCT05506943 |
| Psilocybin | Other | Phase PHASE3 | Major Depressive Disorder | RECRUITING | NCT06247839 |
| Psilocybin | Other | Phase PHASE2 | Post Traumatic Stress Disorder | COMPLETED | NCT05312151 |
| Psilocybin | Other | Phase PHASE2 | Major Depressive Disorder | ACTIVE_NOT_RECRUITING | NCT05733546 |
| Psilocybin | Other | Phase PHASE2 | Major Depressive Disorder | ACTIVE_NOT_RECRUITING | NCT05733546 |
| Psilocybin | Other | Phase PHASE2 | Major Depressive Disorder | ACTIVE_NOT_RECRUITING | NCT05733546 |
| Standard Child-Focused Programming | Other | Approved | Child Development | NOT_YET_RECRUITING | NCT07213102 |
| Integrated Whole-Household Programming | Other | Approved | Child Development | NOT_YET_RECRUITING | NCT07213102 |
| Standard Child-Focused Programming | Other | Approved | Child Development | NOT_YET_RECRUITING | NCT07213102 |
| Integrated Whole-Household Programming | Other | Approved | Child Development | NOT_YET_RECRUITING | NCT07213102 |
| Transcatheter Aortic Valve Replacement (TAVR) | Other | Approved | Aortic Stenosis Treated With TAVI | RECRUITING | NCT06689839 |
| F2 Filter and Delivery System | Other | Approved | Aortic Stenosis Treated With TAVI | RECRUITING | NCT06689839 |
| Psilocybin | Other | Phase PHASE3 | Treatment Resistant Depression | ACTIVE_NOT_RECRUITING | NCT05624268 |
| Psilocybin | Other | Phase PHASE3 | Treatment Resistant Depression | ACTIVE_NOT_RECRUITING | NCT05624268 |
| Psilocybin | Other | Phase PHASE2 | Treatment Resistant Depression | COMPLETED | NCT05220410 |
| Psilocybin | Other | Phase PHASE2 | Treatment Resistant Depression | COMPLETED | NCT05220410 |
| Psilocybin | Other | Phase PHASE3 | Treatment Resistant Depression | ACTIVE_NOT_RECRUITING | NCT05711940 |
| Psilocybin | Other | Phase PHASE3 | Treatment Resistant Depression | ACTIVE_NOT_RECRUITING | NCT05711940 |
| CTX-009 | Other | Phase PHASE1 | Metastatic Biliary Tract Cancer | RECRUITING | NCT06548412 |
| Durvalumab | Other | Phase PHASE1 | Metastatic Biliary Tract Cancer | RECRUITING | NCT06548412 |
| Cisplatin | Other | Phase PHASE1 | Metastatic Biliary Tract Cancer | RECRUITING | NCT06548412 |
| Gemcitabine | Other | Phase PHASE1 | Metastatic Biliary Tract Cancer | RECRUITING | NCT06548412 |
| CTX-471 | Other | Phase PHASE1 | Glioblastoma | NOT_YET_RECRUITING | NCT07392957 |
| CTX-009 | Other | Phase PHASE1 | Glioblastoma | NOT_YET_RECRUITING | NCT07392957 |
| CTX-009 | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT05513742 |
| Pembrolizumab (KEYTRUDA®) | Other | Phase PHASE1 | Locally Advanced Solid Tumor | COMPLETED | NCT03881488 |
| CTX-471 | Other | Phase PHASE1 | Locally Advanced Solid Tumor | COMPLETED | NCT03881488 |
| CTX-8371 | Other | Phase PHASE1 | Non Small Cell Lung Cancer | RECRUITING | NCT06150664 |
| Paclitaxel | Other | Phase PHASE2 | Biliary Tract Cancer | COMPLETED | NCT05506943 |
| CTX-009 | Other | Phase PHASE2 | Biliary Tract Cancer | COMPLETED | NCT05506943 |
| Paclitaxel | Other | Phase PHASE2 | Biliary Tract Cancer | COMPLETED | NCT05506943 |
| CTX-009 | Other | Phase PHASE2 | Biliary Tract Cancer | COMPLETED | NCT05506943 |
| Paclitaxel | Other | Phase PHASE2 | Biliary Tract Cancer | COMPLETED | NCT05506943 |
| CTX-009 | Other | Phase PHASE2 | Biliary Tract Cancer | COMPLETED | NCT05506943 |
| CTX-10726 | Other | Phase PHASE1 | Gastroesophageal Cancer (GC) | RECRUITING | NCT07419841 |
| Paclitaxel | Other | Phase PHASE2 | Biliary Tract Cancer | COMPLETED | NCT05506943 |
| CTX-009 | Other | Phase PHASE2 | Biliary Tract Cancer | COMPLETED | NCT05506943 |
| Paclitaxel | Other | Phase PHASE2 | Biliary Tract Cancer | COMPLETED | NCT05506943 |
| CTX-009 | Other | Phase PHASE2 | Biliary Tract Cancer | COMPLETED | NCT05506943 |
| CTX-10726 | Other | Phase PHASE1 | Gastroesophageal Cancer (GC) | RECRUITING | NCT07419841 |
| Paclitaxel | Other | Phase PHASE2 | Biliary Tract Cancer | COMPLETED | NCT05506943 |
| CTX-009 | Other | Phase PHASE2 | Biliary Tract Cancer | COMPLETED | NCT05506943 |
| CTX-10726 | Other | Phase PHASE1 | Gastroesophageal Cancer (GC) | RECRUITING | NCT07419841 |
| CTX-10726 | Other | Phase PHASE1 | Gastroesophageal Cancer (GC) | RECRUITING | NCT07419841 |
| CTX-10726 | Other | Phase PHASE1 | Gastroesophageal Cancer (GC) | RECRUITING | NCT07419841 |
| CTX-10726 | Other | Phase PHASE1 | Gastroesophageal Cancer (GC) | RECRUITING | NCT07419841 |
| CTX-10726 | Other | Phase PHASE1 | Gastroesophageal Cancer (GC) | RECRUITING | NCT07419841 |
| CTX-10726 | Other | Phase PHASE1 | Gastroesophageal Cancer (GC) | RECRUITING | NCT07419841 |
| CTX-10726 | Other | Phase PHASE1 | Gastroesophageal Cancer (GC) | RECRUITING | NCT07419841 |
| CTX-10726 | Other | Phase PHASE1 | Gastroesophageal Cancer (GC) | RECRUITING | NCT07419841 |
| CTX-10726 | Other | Phase PHASE1 | Gastroesophageal Cancer (GC) | RECRUITING | NCT07419841 |
| CTX-10726 | Other | Phase PHASE1 | Gastroesophageal Cancer (GC) | RECRUITING | NCT07419841 |
| Pembrolizumab (KEYTRUDA®) | Other | Phase PHASE1 | Locally Advanced Solid Tumor | COMPLETED | NCT03881488 |
| CTX-471 | Other | Phase PHASE1 | Locally Advanced Solid Tumor | COMPLETED | NCT03881488 |
| CTX-009 | Other | Phase PHASE2 | Metastatic Colorectal Cancer | COMPLETED | NCT05513742 |
| Psilocybin | DRUG | Phase PHASE3 | Treatment Resistant Depression | ACTIVE_NOT_RECRUITING | NCT05711940 |
| Aortic Stenosis | DEVICE | Approved | Aortic Stenosis | WITHDRAWN | NCT06069661 |
| F2 filter and delivery system | DEVICE | Phase EARLY_PHASE1 | Aortic Stenosis | RECRUITING | NCT05866640 |
| Transcatheter Aortic Valve Replacement (TAVR) | PROCEDURE | Approved | Aortic Stenosis Treated With TAVI | RECRUITING | NCT06689839 |
| F2 Filter and Delivery System | DEVICE | Approved | Aortic Stenosis | COMPLETED | NCT05893082 |
| Psilocybin | DRUG | Phase PHASE2 | Anorexia Nervosa | COMPLETED | NCT04661514 |
| CTX-009 | DRUG | Phase PHASE1 | Metastatic Biliary Tract Cancer | RECRUITING | NCT06548412 |
| Durvalumab | DRUG | Phase PHASE1 | Metastatic Biliary Tract Cancer | RECRUITING | NCT06548412 |
| Cisplatin | DRUG | Phase PHASE1 | Metastatic Biliary Tract Cancer | RECRUITING | NCT06548412 |
| Gemcitabine | DRUG | Phase PHASE1 | Metastatic Biliary Tract Cancer | RECRUITING | NCT06548412 |
Total products: 102